Amarin Targets Novasep as Fourth Supplier of Vascepa API - - BioPharm International

ADVERTISEMENT

Amarin Targets Novasep as Fourth Supplier of Vascepa API



Amarin, a biopharmaceutical company, has filed a supplemental new drug application with FDA seeking approval to make Novasep Group, through its subsidiary Finorga, as an additional supplier of icosapent ethyl, the API in Vaseepa Amarin’s omega-3-fatty acid product supplier. Novasep is part of the previously disclosed Slanmhor consortium with which Amarin announced a global supply agreement in 2012.

Novasep, a provider of purification technologies and API manufacturing, is building a chromatography plant using its proprietary chromatography technologies to produce API on behalf of the Slanmhor consortium and Amarin. Amarin anticipates the Novasep facility, located in Mourenx, France, to be qualified and operational for manufacturing in 2014.

Source: Amarin

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

PDA Announces Technical Report on Drug Shortages
September 9, 2014
European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
DPT Laboratories Acquires Media Pharmaceuticals' Lakewood Facilities
September 5, 2014
Merck KGaA Breaks Ground on Facility in China
September 5, 2014
FDA Releases Guidance Electronic Submission of Lot Distribution Reports
September 5, 2014
Author Guidelines

Click here